Description: VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Home Page: www.vita34.de
Deutscher Platz 5a
Leipzig,
04103
Germany
Phone:
49 341 48792 40
Officers
| Name | Title |
|---|---|
| Mr. Jakub Julian Baran | Chairman of the Management Board & CEO |
| Mr. Tomasz Franciszek Baran | Vice President of the Management Board & Chief Commercial Officer |
| Thomas Pfaadt | Chief Financial Officer |
| Santiago Luengo | Managing Director of Secuvita |
Exchange: XETRA
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Providers & Services |
| GIC Sub-Industry: | Health Care Facilities |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 23.7647 |
| Price-to-Book MRQ: | 2.8998 |
| Price-to-Sales TTM: | 0.9111 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 745 |